Forest Labs, TransTech Pharma Enter License Deal

TransTech Pharma and Forest Laboratories have entered into a license agreement for the development and commercialization of small molecule compounds discovered by TransTech. These compounds are functionally liver-selective Glucokinase Activators (GKAs), which represent a new class of glucose-lowering agents for the treatment of diabetes.

TransTech will receive an upfront license payment of $50 million and is eligible to receive as much as $1.1 billion in upfront and milestone payments for the successful development and commercialization of the GKA compounds. TransTech will also receive royalties on worldwide product sales and will be responsible for development and commercialization costs. TransTech retains the rights to the Middle East and North Africa, while Forest has exclusive rights to the rest of the world markets. The portfolio licensed by Forest includes a lead compound, TTP399, which has completed Phase I studies, and other compounds in Phase I and preclinical stages of development.

Adnan M. M. Mjalli, Ph.D., founder, chairman and chief executive officer of TransTech Pharma, said, “We are excited to be partnering our GKA program with Forest. We selected Forest because of its highly dedicated team and leadership that bring a wealth of experience and resources to our compounds. Forest is driven by entrepreneurial spirit, innovation and dedication. We believe this novel class of compounds has the potential to be a major therapeutic advance in the treatment of diabetes.”


Contracting & Outsourcing 2010: FDA Keynote Added!
CAPT Joseph McGinnis will deliver the FDA Keynote on Compliance Enforcement Updates on Friday, Sept. 24 at Contracting & Outsourcing 2010!

Click here to visit our conference website